| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.22 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Several studies associated Major Depressive Disorder (MDD) with an increased production of pro-inflammatory cytokines, such as interleukin 6 (IL-6). Serum IL-6 levels were found to be significantly increased in subjects with MDD and with Treatment Resistant Depression (TRD). Moreover, ketamine, a drug with fast-acting antidepressant properties, has proven to reduce IL-6 levels in rat prefrontal cortex and hippocampus. However, despite the clear influence of IL-6 in the pathophysiology of depression and in antidepressant response, studies evaluating the impact of IL-6 functional genetic polymorphisms on treatment response phenotypes are scarce.
Description
Keywords
Citation
Santos, M., Lima, L., Mota-Pereira, J., Cruz, A., Medeiros, R., Carvalho, S., Pimentel, P., Maia, D., Correia, D., & Gomes, S. (2014). EPA-1313—Influence of il6-174g>c, il6-6331t>c and il6r d358a a>c il-6 genetic polymorphisms in antidepressant treatment phenotypes. Abstracts of the 22nd European Congress of Psychiatry, 29, 1. https://doi.org/10.1016/S0924-9338(14)78532-3
Publisher
Elsevier